Regeneron faces very low AGI disruption risk — it makes physical biologic drugs for human diseases, and AGI is far more likely to accelerate its drug discovery pipeline than threaten its business model.
Regeneron is a leading biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious medical conditions. The company is best known for Eylea (eye disease), Dupixent (inflammatory diseases), and Libtayo (cancer). Regeneron has significant in-house R&D capabilities including its proprietary VelociSuite technology platform for drug discovery, and it manufactures its own biologic drugs at facilities in New York and Ireland.
Regeneron's customers are primarily specialty pharmacies, wholesalers/distributors (McKesson, AmerisourceBergen, Cardinal Health), hospitals, ophthalmologists, dermatologists, allergists, and oncologists who prescribe its drugs. End patients include those with inflammatory conditions, eye diseases, and cancers. Sanofi is a major commercial partner for Dupixent.
Regeneron discovers, develops, and manufactures biologic drugs (monoclonal antibodies like Dupixent, Eylea, Libtayo). These are physical molecules injected into human bodies to treat real diseases. AGI cannot replace the need for these therapies. Drug manufacturing requires massive bioprocessing facilities, not code. Regeneron's customers are patients, hospitals, insurers, and healthcare systems. Disease does not disappear because AGI exists. In fact, an aging global population ensures sustained demand. These customers are not IT companies or knowledge workers — they are the healthcare system itself.